EUVIMEDEUVIMED entdecken
Crossref

Radiolabeling of Trastuzumab With Technetium‐99m [99mTc] as a Radioligand for Screening Mentha pulegium on HER‐2 Receptors

Narges Aryanpour, Golrokh Farnam, Farshad H Shirazi, Soraya Shahhosseini

Journal of Labelled Compounds and Radiopharmaceuticals · 2026

DOI: 10.1002/jlcr.70006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2026. Verfasst von Narges Aryanpour und 3 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Trastuzumab, Erb-b2 Receptor Tyrosine Kinases, Technetium, Radiopharmaceuticals. Die Arbeit nennt 46 Literaturangaben. Gefördert von: Pharmaceutical Science Research Center, School of Pharmacy, Shahid Beheshti University of Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of medicinal plants as anti‐cancer agents has attracted the attention of researchers. A method is needed for screening the anti‐cancer effects on HER‐2 receptors. In this study, a simple method based on radioligand binding studies was developed for primary screening of medicinal plants on HER‐2 receptors in vitro. Trastuzumab was conjugated to HYNIC in a chemical reaction using NHS‐HYNIC. HYNIC‐Trastuzumab was radiolabeled with [99mTc] using SnCl 2 as a reducing agent and tricine as a coligand. Biological activities of [99mTc]Tc‐HYNIC‐Trastuzumab were determined in saturation binding studies using the SKBR3 cell line. The IC 50 of Mentha pulegium was determined in competition with [99mTc]Tc‐HYNIC‐Trastuzumab on the SKBR3 cell line. Radiochemical purity was ≥ 90% ± 2.08%. Based on the results, radiolabeled Trastuzumab maintained its biological activity after labeling (immunoreactivity = 83%, K d = 7.049 ± 1.861 nM). The IC 50 of Mentha pulegium was 31.3 ± 1.3 μg/mL. [99mTc]Tc‐HYNIC‐Trastuzumab can be used as a radioligand in competition binding studies for primary screening of medicinal plants, peptides, and small molecules in vitro on HER‐2 receptors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TrastuzumabErb-b2 Receptor Tyrosine KinasesTechnetiumRadiopharmaceuticalsOrganotechnetium CompoundsHumansCell Line, TumorIsotope Labeling

Substanzen

TrastuzumabErb-b2 Receptor Tyrosine KinasesTechnetiumRadiopharmaceuticalsOrganotechnetium CompoundsERBB2 protein, human

Autor:innen und Institutionen

  • Pharmaceutical Sciences Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Toxicology and Pharmacology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Department of Pharmaceutical Chemistry and Radiopharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
  • Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Förderung

  • Pharmaceutical Science Research Center
  • School of Pharmacy, Shahid Beheshti University of Medical Sciences

Zitieren

APA

Aryanpour, N., Farnam, G., Shirazi, F. H., & Shahhosseini, S. (2026). Radiolabeling of Trastuzumab With Technetium‐99m [99mTc] as a Radioligand for Screening Mentha pulegium on HER‐2 Receptors. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.70006

Vancouver

Aryanpour N, Farnam G, Shirazi FH, Shahhosseini S. Radiolabeling of Trastuzumab With Technetium‐99m [99mTc] as a Radioligand for Screening Mentha pulegium on HER‐2 Receptors. Journal of Labelled Compounds and Radiopharmaceuticals. 2026. doi:10.1002/jlcr.70006

BibTeX
@article{Aryanpour2026,
  author = {Aryanpour, Narges and Farnam, Golrokh and Shirazi, Farshad H and Shahhosseini, Soraya},
  title = {Radiolabeling of Trastuzumab With Technetium‐99m [99mTc] as a Radioligand for Screening Mentha pulegium on HER‐2 Receptors},
  journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
  year = {2026},
  doi = {10.1002/jlcr.70006}
}
Kostenlos starten →